Piper Sandler Calls Beta Bionics, Inc. (BBNX) 'A Unique Diabetes Name to Own'
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $26.00 price target on Beta Bionics, Inc. (NASDAQ: BBNX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
